Those who have taken the time to listen to the latest Earnings Conference Call with CEO and Chairman Michael Farrell will view this latest quarter as very exciting. I have mentioned the two global megatrends that are taking place that I too believe are going to support Resmed's growth going forward - the wearables market (many players now moving into this space) and the big pharmaceutical companies as they continue their research into sleep apnea. What I believe this is going to do is drive more "motivated" patients into Resmed's funnel. Clearly, that's what's starting to funnel through and note the sleep tracking wearables market hasn't even taken off yet. In Q3 2024 Resmed had 660,000 patients in their cohort with prescriptions for both GLP-1 medications and positive airway pressure therapy. They've now increased that to 811,000 patients in their cohort. That's an additional 151,000 patients in ONE quarter! I wouldn't brush over these numbers lightly folks. They're doing a phenomenal job.
Tony
Those who have taken the time to listen to the latest Earnings...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$33.71 |
Change
0.390(1.17%) |
Mkt cap ! $21.66B | |||
| Open | High | Low | Value | Volume |
| $33.41 | $33.71 | $33.41 | $54.92M | 1.633M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 140 | $33.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $33.72 | 36 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| RMD (ASX) Chart |